Predicting skeletal complications in metastatic breast cancer raises challenges
- 6 August 2010
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Breast Cancer Research and Treatment
- Vol. 123 (3), 781-783
- https://doi.org/10.1007/s10549-010-1104-8
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidityBMC Cancer, 2009
- Patterns of Bisphosphonate Use in the United States in the Treatment of Metastatic Bone DiseaseClinical Breast Cancer, 2007
- Clinical Features of Metastatic Bone Disease and Risk of Skeletal MorbidityClinical Cancer Research, 2006
- Bisphosphonates for breast cancerPublished by Wiley ,2005
- Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 2005
- Clinical Benefit of Zoledronic Acid in Patients with Lung Cancer and OtherSolid Tumors: Analysis Based on History of Skeletal ComplicationsClinical Lung Cancer, 2004
- American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast CancerJournal of Clinical Oncology, 2003
- Metastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treatment Reviews, 2001
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesThe New England Journal of Medicine, 1996
- Metastatic Disease in Long Bones A Proposed Scoring System for Diagnosing Impending Pathologic FracturesClinical Orthopaedics and Related Research, 1989